Gaziano TA, Fonarow GC, Velazquez EJ, et al. - Researchers utilized data on US patients experiencing heart failure with reduced ejection fraction (HFrEF) who were eligible for sacubitril-valsartan therapy, to estimate the cost-effectiveness of inpatient commencement of sacubitril-valsartan vs enalapril relative to no initiation or posthospitalization initiation of sacubitril-valsartan in stabilized patients suffering from HFrEF. They used a 5-state Markov model with all-cause death, HF, and non-HF hospitalization probabilities. According to the findings, decreased hospitalizations, increased quality-adjusted life expectancy, and cost savings, all may be achieved in correlation with initiation of sacubitril-valsartan during hospitalization, vs no initiation or initiation after hospitalization, in patients with HFrEF. Up to $449 per person for 1 year or $2550 per person over 5 years were saved with inpatient initiation of sacubitril-valsartan vs continuation of enalapril, as shown in a budget analysis.